NASDAQ:GANX Gain Therapeutics (GANX) Stock Forecast, Price & News $4.86 -0.20 (-3.95%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$4.80▼$5.2250-Day Range$4.50▼$5.5052-Week Range$2.80▼$6.19Volume70,861 shsAverage Volume51,844 shsMarket Capitalization$59.92 millionP/E RatioN/ADividend YieldN/APrice Target$8.15 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Gain Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside67.7% Upside$8.15 Price TargetShort InterestHealthy0.57% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.54) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector287th out of 982 stocksPharmaceutical Preparations Industry134th out of 483 stocks 3.4 Analyst's Opinion Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.15, Gain Therapeutics has a forecasted upside of 67.7% from its current price of $4.86.Amount of Analyst CoverageGain Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.57% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 7.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GANX. Previous Next 2.8 News and Social Media Coverage News SentimentGain Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Gain Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GANX on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.21% of the stock of Gain Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gain Therapeutics are expected to grow in the coming year, from ($1.54) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Gain Therapeutics (NASDAQ:GANX) StockGain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.Read More Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GANX Stock News HeadlinesJune 1, 2023 | finance.yahoo.comGain Therapeutics to Present at the Jefferies Healthcare ConferenceMay 20, 2023 | americanbankingnews.comChardan Capital Brokers Cut Earnings Estimates for Gain Therapeutics, Inc. (NASDAQ:GANX)June 7, 2023 | Edge On The Street (Ad)146 Pounds of Graphite Needed for Each EVGraphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.May 17, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Gain Therapeutics, Inc.'s Q4 2023 Earnings (NASDAQ:GANX)May 16, 2023 | americanbankingnews.comGain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Down 7.1% in AprilMay 15, 2023 | msn.comChardan Capital Maintains Gain Therapeutics (GANX) Buy RecommendationMay 15, 2023 | markets.businessinsider.comWhere Gain Therapeutics Stands With AnalystsMay 15, 2023 | markets.businessinsider.comAnalyst Expectations for Gain Therapeutics's FutureJune 7, 2023 | Edge On The Street (Ad)146 Pounds of Graphite Needed for Each EVGraphite - not lithium - is the largest component of lithium-ion batteries used in electric vehicles. That's why 97 more graphite mines will be needed by 2035 just to keep up with battery demand for the $7 trillion EV market.May 13, 2023 | finance.yahoo.comGain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports First Quarter 2023 Financial Results and Business UpdateMay 12, 2023 | finance.yahoo.comGain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2023 | finance.yahoo.comGain Therapeutics Reports First Quarter 2023 Financial Results and Business UpdateMay 8, 2023 | finance.yahoo.comAnalysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out forMay 3, 2023 | marketwatch.comGain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's DiseaseMay 3, 2023 | finance.yahoo.comGain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s DiseaseMay 1, 2023 | msn.comHC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy RecommendationMay 1, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Gain Therapeutics (GANX)April 22, 2023 | finance.yahoo.comGain Therapeutics, Inc. (GANX) stock forecast and price targetApril 12, 2023 | finance.yahoo.comGain Therapeutics Appoints C. Evan Ballantyne as Chief Financial OfficerApril 1, 2023 | americanbankingnews.comChardan Capital Weighs in on Gain Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:GANX)March 30, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Gain Therapeutics (GANX)March 29, 2023 | finance.yahoo.comGain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 MeetingMarch 28, 2023 | finanznachrichten.deGain Therapeutics, Inc.: Gain Therapeutics Reports Full Year 2022 Financial Results and Business UpdateMarch 27, 2023 | americanbankingnews.comChardan Capital Raises Gain Therapeutics (NASDAQ:GANX) Price Target to $5.75March 23, 2023 | finance.yahoo.comGain Therapeutics Reports Full Year 2022 Financial Results and Business UpdateMarch 22, 2023 | finance.yahoo.comGain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion LeadersSee More Headlines GANX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GANX Company Calendar Last Earnings3/23/2023Today6/06/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GANX CUSIPN/A CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.15 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+67.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,590,000.00 Net MarginsN/A Pretax Margin-12,898.67% Return on Equity-92.98% Return on Assets-73.67% Debt Debt-to-Equity Ratio0.03 Current Ratio3.75 Quick Ratio3.75 Sales & Book Value Annual Sales$140,000.00 Price / Sales428.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book3.06Miscellaneous Outstanding Shares12,330,000Free Float10,973,000Market Cap$59.92 million OptionableNot Optionable Beta0.37 Key ExecutivesDr. Khalid Islam Ph.D. (Age 67)Founder & Chairman Comp: $60kMr. Matthias Alder LIC. IUR. (Age 57)LL.M., COO, CEO & Director Comp: $414.29kMr. Salvatore Calabrese (Age 52)CFO & Corp. Sec. Comp: $345.39kMr. Gianluca Fuggetta (Age 34)Principal Accounting Officer Dr. Xavier Barril Ph.D.Chief Technology OfficerDr. Manolo Bellotto Ph.D. (Age 51)GM & Chief Strategy Officer Dr. Ana Maria Garcia-Collazo Ph.D.Head of ResearchDr. Natalia Perez-Carmona Ph.D.Head of BiologyDr. Joanne Taylor Ph.D.Sr. VP of Research & Scientific AdvisorDr. Terenzio Ignoni Pharm.D.Sr. VP of Technical OperationsMore ExecutivesKey CompetitorsAdageneNASDAQ:ADAGHomology MedicinesNASDAQ:FIXXAbeona TherapeuticsNASDAQ:ABEOEnochian BiosciencesNASDAQ:ENOBAnebulo PharmaceuticalsNASDAQ:ANEBView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 4,093 shares on 5/16/2023Ownership: 0.775%Susquehanna International Group LLPBought 15,172 shares on 5/16/2023Ownership: 0.125%Renaissance Technologies LLCBought 5,500 shares on 5/12/2023Ownership: 0.318%Dimensional Fund Advisors LPBought 6,661 shares on 5/12/2023Ownership: 0.153%NewEdge Advisors LLCBought 10,500 shares on 5/12/2023Ownership: 0.086%View All Institutional Transactions GANX Stock - Frequently Asked Questions Should I buy or sell Gain Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares. View GANX analyst ratings or view top-rated stocks. What is Gain Therapeutics' stock price forecast for 2023? 5 brokerages have issued 12-month price targets for Gain Therapeutics' shares. Their GANX share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $8.15 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View analysts price targets for GANX or view top-rated stocks among Wall Street analysts. How have GANX shares performed in 2023? Gain Therapeutics' stock was trading at $3.13 at the start of the year. Since then, GANX shares have increased by 55.3% and is now trading at $4.86. View the best growth stocks for 2023 here. Are investors shorting Gain Therapeutics? Gain Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 55,100 shares, a drop of 7.9% from the April 30th total of 59,800 shares. Based on an average trading volume of 83,600 shares, the short-interest ratio is currently 0.7 days. Currently, 0.6% of the company's stock are short sold. View Gain Therapeutics' Short Interest. When is Gain Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our GANX earnings forecast. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. When did Gain Therapeutics IPO? (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager. What is Gain Therapeutics' stock symbol? Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX." Who are Gain Therapeutics' major shareholders? Gain Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.77%), CM Management LLC (0.74%), Renaissance Technologies LLC (0.32%), Raymond James & Associates (0.17%), Dimensional Fund Advisors LP (0.15%) and Susquehanna International Group LLP (0.12%). View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gain Therapeutics' stock price today? One share of GANX stock can currently be purchased for approximately $4.86. How much money does Gain Therapeutics make? Gain Therapeutics (NASDAQ:GANX) has a market capitalization of $59.92 million and generates $140,000.00 in revenue each year. The company earns $-17,590,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. How can I contact Gain Therapeutics? Gain Therapeutics' mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The official website for the company is www.gaintherapeutics.com. The company can be reached via phone at 301-500-1556 or via email at ir@gaintherapeutics.com. This page (NASDAQ:GANX) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.